Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b/3 Study of Icotrokinra in Moderately to Severely Active Crohn's Disease
2025-521382-27-00Phase 3Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2025
- Modality
- Peptides
- Countries
- 28
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing Icotrokinra with Placebo (2 arms). Primary endpoints: Phase 2b Induction: clinical response at Week I-12, Phase 3 Induction: clinical remission at Week I-12 and 3 more. Planned start Dec 2025; status: authorised.
02
Drugs
icotrokinra
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2025-521382-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521382-27-00.